文献速递胸部肿瘤

EGFR突变非小细胞肺癌中HIF-1α调控异常与VEGF依赖表型

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
PubMed 文献 · J Thorac Oncol · 2020-12-09

该研究在体外和体内非小细胞肺癌模型中分析EGFR抑制对VEGF和HIF-1α的影响。EGFR突变细胞中EGFR而非缺氧主导HIF-1α和VEGF调控,EGFR突变肿瘤对VEGF抑制更敏感,联合治疗延缓进展。获得性EGFR抑制剂耐药后HIF-1α和VEGF仍高表达但与EGFR信号脱偶联,支持在EGFR抑制剂初治和难治阶段靶向VEGF。

要点

  • EGFR突变NSCLC中EGFR信号而非缺氧主导HIF-1α和VEGF调控。
  • EGFR突变肿瘤对VEGF抑制比野生型更敏感,联合治疗延缓进展。
  • 获得性耐药后HIF-1α和VEGF仍高表达但与EGFR信号脱偶联。

核心结论

  • EGFR突变NSCLC中EGFR信号以非缺氧依赖方式主导HIF-1α和VEGF调控,劫持了调控肿瘤侵袭性的重要细胞反应。
  • 获得性EGFR抑制剂耐药细胞保留HIF-1α和VEGF高表达,且这些通路不再受EGFR调控。
  • 结果支持在EGFR突变肿瘤的EGFR抑制剂初治和难治阶段靶向VEGF。

研究设计与样本

  • 在体外和体内NSCLC模型中分析EGFR抑制对VEGF和HIF-1α的影响。
  • 在异种移植瘤中测定VEGF抑制的疗效,并分析获得性EGFR抑制剂耐药对VEGF和HIF-1α的影响。

主要发现

  • 与EGFR野生型细胞相比,携带EGFR激活突变的NSCLC细胞表现出VEGF调控改变。
  • EGFR突变细胞中EGFR而非缺氧是HIF-1α和VEGF的主导调控因子。
  • 携带经典或外显子20 EGFR突变的NSCLC肿瘤模型对VEGF抑制比EGFR野生型肿瘤更敏感。
  • VEGF与EGFR联合抑制延缓肿瘤进展。
  • 获得性EGFR抑制剂耐药模型中VEGF仍过表达,但HIF-1α的非缺氧依赖表达与EGFR信号脱偶联,EGFR抑制不再降低HIF-1α或VEGF表达。

临床怎么用

  • 在EGFR突变NSCLC的EGFR抑制剂初治阶段可考虑联合VEGF靶向治疗。
  • 在EGFR抑制剂难治阶段仍可考虑靶向VEGF,因HIF-1α和VEGF持续高表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that EGFR mutation status may define a patient subgroup with greater benefit from VEGF blockade. The mechanisms driving this potentially enhanced VEGF dependence are unknown. METHODS: We analyzed the effect of EGFR inhibition on VEGF and HIF-1α in NSCLC models in vitro and in vivo. We determined the efficacy of VEGF inhibition in xenografts and analyzed the impact of acquired EGFR inhibitor resistance on VEGF and HIF-1α. RESULTS: NSCLC cells with EGFR-activating mutations exhibited altered regulation of VEGF compared with EGFR wild-type cells. In EGFR-mutant cells, EGFR, not hypoxia, was the dominant regulator of HIF-1α and VEGF. NSCLC tumor models bearing classical or exon 20 EGFR mutations were more sensitive to VEGF inhibition than EGFR wild-type tumors, and a combination of VEGF and EGFR inhibition delayed tumor progression. In models of acquired EGFR inhibitor resistance, whereas VEGF remained overexpressed, the hypoxia-independent expression of HIF-1α was delinked from EGFR signaling, and EGFR inhibition no longer diminished HIF-1α or VEGF expression. CONCLUSIONS: In EGFR-mutant NSCLC, EGFR signaling is the dominant regulator of HIF-1α and VEGF in a hypoxia-independent manner, hijacking an important cellular response regulating tumor aggressiveness. Cells with acquired EGFR inhibitor resistance retained elevated expression of HIF-1α and VEGF, and the pathways were no longer EGFR-regulated. This supports VEGF targeting in EGFR-mutant tumors in the EGFR inhibitor-naive and refractory settings.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nilsson MB, Robichaux J, Herynk MH, et al. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2020. PMID: 33309987. doi:10.1016/j.jtho.2020.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。